1325 Boylston Street
About Decibel TherapeuticsDecibel Therapeutics is a hearing company focused on discovering and developing new therapies to protect, repair and restore hearing. By combining recent innovations in hearing science with leading diagnostic tools, biological insights, modeling and therapeutic delivery techniques, Decibel is pioneering a comprehensive approach to define the underlying biological causes of hearing loss and develop a pipeline of breakthrough therapies targeted to specific indications and populations. Founded by the world’s preeminent experts in hearing loss, Decibel Therapeutics was launched in 2015 by Third Rock Ventures and is headquartered in Cambridge, Mass.
President and CEO: Steven Holtzman
CMO: Leslie Shinobu, M.D., Ph.D.
Vice President, Pharmacology: Ada Silos-Santiago, Ph.D.
October 15, 2015: $52 Million Series A From GlaxoSmithKline, SR One and Third Rock Ventures.
37 articles with Decibel Therapeutics
Decibel Therapeutics Announces DB-020 Has Been Granted Fast Track Designation by the U.S. Food and Drug Administration
Decibel Therapeutics , a clinical-stage biotechnology company dedicated to discovering and developing transformative treatments to restore and improve hearing and balance, today announced that their clinical product candidate, DB-020, has been granted Fast Track designation by the U.S. Food and Drug Administration (FDA). DB-020 is an investigational therapy for the prevention of cisplatin-induced hearing loss, a serious and debi
Decibel Therapeutics Announces $82M Series D Financing to Advance Gene Therapies to Restore Hearing and Balance
Proceeds support advancement of lead gene therapy programs and accelerate development of therapeutics to restore functional hair cells in the inner ear
Decibel Therapeutics Announces Exclusive Licensing Agreements for Hearing Loss Gene Therapy Technology
Decibel Therapeutics , a clinical-stage biotechnology company developing novel restorative gene therapeutics to treat hearing loss and balance disorders, today announced exclusive license agreements with the University of Florida (UF) and the University of California, San Francisco (UCSF) for an adeno-associated virus (AAV) gene therapy technology designed to restore hearing to individuals with profound, congenital hearing loss c
Like almost all conferences this year, Citi’s 15th Annual BioPharma Conference 2020 is being held virtually.
Decibel Therapeutics, a clinical-stage biotechnology company developing novel gene therapeutics for restoration of hearing loss and balance disorders, today announced that Laurence Reid Ph.D., Chief Executive Officer of Decibel, will present at Citi's 15th Annual BioPharma Virtual Conference on Tuesday, September 8, 2020 at 1:10pm ET. About Decibel Therapeutics Decibel Therapeutics is a clinical-stage biotechnology co
Decibel Therapeutics to Present at the 23rd Annual Meeting of the American Society of Gene & Cell Therapy (ASGCT)
Decibel Therapeutics to Present at the 23 rd Annual Meeting of the American Society of Gene & Cell Therapy (ASGCT)
Decibel Therapeutics Publishes Results from Early-Stage Study of Therapy Designed to Prevent Hearing Loss Associated with Cisplatin Chemotherapy
Decibel Therapeutics , today announced that Phase 1a trial results demonstrating the safety and tolerability of its lead candidate, DB-020, have been published in the peer-reviewed journal Investigational New Drugs . DB-020 is being developed for the prevention of cisplatin-induced hearing loss. The
1/31/2020Pharma and biotech companies strengthen their leadership teams and boards with this week's Movers & Shakers.
Decibel Therapeutics, a development-stage biotechnology company developing novel therapeutics for hearing loss and balance disorders, today announced a new strategic research focus on regenerative medicine approaches for the inner ear
Decibel Therapeutics, a development-stage biotechnology company advancing novel therapeutics for hearing loss and balance disorders, today announced that industry veteran Laurence Reid, Ph.D., has been appointed as Decibel’s acting chief executive officer, bringing deep experience in biotech company building.
Decibel Therapeutics to Present at the 43rd Annual Association for Research in Otolaryngology (ARO) Conference
Decibel Therapeutics, a development-stage biotechnology company creating novel therapeutics for hearing loss and balance disorders, will present new findings from several of their drug discovery and development programs at the 43rd annual meeting of the Association for Research in Otolaryngology, which is being held from January 25-29 in San Jose, CA.
Decibel Therapeutics, a clinical-stage biotechnology company developing novel therapeutics for hearing loss and balance disorders, will provide a corporate update at the upcoming Jefferies Gene Therapy Summit in New York City on Tuesday, October 8, 2019 at 9:45 a.m. ET.
Biotech and pharma companies tap new members of executive leadership teams and boards.
Decibel Therapeutics Appoints Healthcare Industry Veteran Christine A. Poon to its Board of Directors
Decibel Therapeutics, a clinical-stage biotechnology company developing novel therapeutics for hearing loss and balance disorders, announced the appointment of Christine Poon to its board of directors.
4G Clinical today announced a partnership with Decibel Therapeutics to enable complex trial designs for the development of novel therapies for hearing and balance disorders.
2/8/2019In this week's edition of Movers and Shakers, biopharma companies tap executives to serve in various leadership roles.
Decibel Therapeutics will showcase capabilities across its inner ear-focused drug discovery and development platform at the 42nd annual mid-winter meeting of the Association for Research in Otolaryngology from February 9-13, 2019.
Decibel Therapeutics Bolsters Leadership Team with Appointments of Chief Medical Officer and Chief Operating Officer
Decibel Therapeutics today announced the appointment of leading otolaryngologist Dr.
Decibel Therapeutics and Cocoon Biotech Announce Collaboration to Develop Proprietary Formulations for Delivery of Medicines to the Inner Ear
Decibel Therapeutics and Cocoon Biotech announced a research collaboration to apply Cocoon's proprietary silk fibroin platform to the development of therapeutics for hearing and balance disorders
Among life on earth, mammals are some of the only creatures that can’t regenerate damaged hearing. Birds, frogs, fish, they all have the ability to regenerate sensory hair cells after they’re damaged.